1 / 40

Infective Endocarditis

Infective Endocarditis. Supervisor : Dr: Mohammed Al marwala Presented by : Dr : Areej Aljabali. Items of Presentation General definitions Pathology Pathogenesis Pathophysiology Clinical features Diagnosis Treatment Prevention . Definition :

melita
Télécharger la présentation

Infective Endocarditis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Infective Endocarditis Supervisor : Dr: Mohammed Al marwala Presented by : Dr :AreejAljabali

  2. Items of Presentation General definitions Pathology Pathogenesis Pathophysiology Clinical features Diagnosis Treatment Prevention

  3. Definition : Infective endocarditis is characterized by colonization or invasion of the heart valves or the mural endocardium by a microbe, leading to the formation of bulky friable vegetations composed of thromb and organisms, often associated with destruction of the underlying cardiac tissues.

  4. Acute • Toxic presentation • Progressive valve destruction & metastatic infection developing in days to weeks • Most commonly caused by S. aureus • Sub acute • Mild toxicity • Presentation over weeks to months • Rarely leads to metastatic infection • Most commonly S. viridans or enterococcus

  5. 55-75% of patients with native valve endocarditis (NVE) have underlying valve abnormalities • MVP • Rheumatic • Congenital • I.v. drug abuse • 7-25% of cases involve prosthetic valves • 25-45% of cases predisposing condition can not be identified

  6. Pathology : • NVE infection is largely confined to leaflets • PVE infection commonly extends beyond valve ring into annulus/peri annular tissue • Ring abscesses • Septal abscesses • Fistulae • Prosthetic dehiscence • Invasive infection more common in aortic position and if onset is early

  7. Pathogenesis : Endothelial damage Platelet-fibrin thrombi Microorganism adherence

  8. Nonbacterial Thrombotic Endocarditis • Endothelial injury • Hypercoagulable state • Lesions seen at coaptation points of valves • Atrial surface mitral/tricuspid • Ventricular surface aortic/pulmonic • Modes of endothelial injury • High velocity jet • Flow from high pressure to low pressure chamber • Flow across narrow orifice of high velocity • Bacteria deposited on edges of low pressure or site of jet impaction

  9. :Pathophysiology • Clinical manifestations • Direct • Constitutional symptoms of infection (cytokine) • Indirect • Local destructive effects of infection • Embolization – septic or bland • Hematogenous seeding of infection may present as local infection or persistent fever, metastatic abscesses may be small • Immune response • Immune complex or complement-mediated

  10. Local destructive effects • Valvular distortion/destruction • Chordal rupture • Perforation/fistula formation • Paravalvular abscess • Conduction abnormalities • Purulent pericarditis • Functional valve obstruction

  11. Embolization • Clinically evident 11 – 43% of patients • Pathologically present 45 – 65% • High risk for embolization • Large > 10 mm vegetation • Hypermobile vegetation • Mitral vegetations (esp. anterior leaflet) • Pulmonary (septic) – 65 – 75% of i.v. drug abusers with tricuspid IE

  12. : Clinical Features • Fever, chills, weakness, lethargy, weight loss, flu-like illness (not always present) • Longstanding IE (rarely seen now with earlier diagnosis): splinter haemorrhages, Janeway lesions, Osler nodes, Roth spots • Murmurs are present in 80 - 85% of patients with left sided IE

  13. Splinter Haemorrhages

  14. Janeway Lesions

  15. Osler Nodes

  16. Roth Spots

  17. In IVDU right sided IE usually affect the tricuspid valve & occasionally the pulmonary valve, instead of systemic issues pulmonary embolism is the most important complication which can evolve into: • Pulmonary infarction • Pulmonary abscess • Bilateral pneumothoraces • Pleural effusion • Empyema

  18. The severity of valvular destruction depends on virulence of infecting organism & infection duration • Heart failure can be the initial presentation

  19. : Diagnosis Modified Duke criteria It is based on clinical, microbiological & echo findings providing high sensitivity & specificity (~80%) for diagnosis of IE when applied to patients with native valve IE with +ve BC

  20. Modified Duke Criteria • Major Criteria: Positive blood cultures Typical microorganism for IE from 2 separate blood culures Viridanssreptococci Sreptococcusbovis HACEK group Saph . Auresus Community acquired enerococci , in the absence of primary focus

  21. Persistently positive blood culture , defined as recovery of a microorganism consistent with IE from: Blood culture drawn more than 12 h apart OR All of 3or majority of 4 or more separate blood cultures , with first last drawn at least one h apart Single positive blood culture for Coxiellaburnetiior antiphase I IgG AB titer more than 1: 800

  22. Evidence of endocardial involvement Positive echocardiogram for IE • TEE recommended in patients with PV ,rated at least possible IE by clinical crieria ,or complicated IE ( paravalvular abscess ) TTE as first test in other patients

  23. Definition of positive ECHO - Oscillating intracardiac mass, on valve or supporting structures , or in the path or regurgitant jets , or on implanted material , in he absence of an alternative anatomic explanation - Intracardiac abscess - New partial dehiscence of prosthetic valve New valvular regurgitation Increase in or change in preexisting murmur not sufficent

  24. Minor Criteria • Predisposition such as a heart condition or IV drug use • Fever • Vascular phenomena - major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial haemorrhage, conjunctivalhaemorrhage, & Janeway lesions

  25. immunological phenomena – glomerulonephritis , Osler s nodes , Roth spots , rheumatoid factor • Other microbial evidence - serological tests, or a positive blood culture but does not meet a major criteria ( excluding single positive cultures for coagulase negative staph and organisms that do not cause endocarditis )

  26. Definite IE 2 major criteria OR 1 major + 3 minor OR 5 minor criteria Possible IE 1 major + 1 minor OR 3 minor

  27. Rejected : Firm alternate diagnosis for manifestation of endocarditisOR Resolution of manifestation of endocarditis , with antibiotic therapy for 4 days or less OR No pathologic evidence of IE at surgery or autopsy after antibiotic therapy for 4 days or less Does not meet criteria for possible IE , as above

  28. TREATMENT : Goals of Therapy Eradicate infection Definitively treat sequelae of destructive intra-cardiac and extra-cardiac lesions

  29. : Antibiotics • Benzylpenicillin is the first choice for Streptococcus or Enterococcus penicillin-susceptible strains • Empirical treatment; flucloxacillin& gentamicin are the usual first line • Vancomycin is used in pts with intracardiac prosthetic material or suspected MRSA • For vanc-resistant MRSA: teicoplanin, lipopeptidedaptomycinor oxazilidones (linezolid) is recommended

  30. IV Abx is normally continued for 4-6 weeks, with the aim of sterilising the vegetations

  31. Indications for Cardiac Surgical Intervention in Patients with Endocarditis Surgery required for optimal outcome • Moderate to severe congestive heart failure due to valve dysfunction • Partially dehisced unstable prosthetic valve • Persistent bacteremia despite optimal antimicrobial therapy • Lack of effective microbicidal therapy (e.g., fungal or Brucellaendocarditis) • S. aureus prosthetic valve endocarditis with an intracardiac complication • Relapse of prosthetic valve endocarditis after optimal antimicrobial therapy

  32. Surgery to be strongly considered for improved outcomea • Perivalvular extension of infection • Poorly responsive S. aureusendocarditis involving the aortic or mitral valve • Large (>10-mm diameter) hypermobile vegetations with increased risk of embolism • Persistent unexplained fever (10 days) in culture-negative native valve endocarditis • Poorly responsive or relapsed endocarditis due to highly antibiotic-resistant enterococci or gram-negative bacilli

  33. Complications • Congestive heart failure • Most common complication • Main indication to surgical treatment • ~60% of IE patients • Uncontrolled infection • Persisting infection • Perivalvular extension in infective endocarditis • Systemic embolism • Brain, spleen and lungs • 30% of IE patients • May be the first symptom

  34. Neurologic events • Acute renal failure • Rheumatic problems • Myocarditis

  35. High-Risk Cardiac Lesions for Which Endocarditis Prophylaxis Is Advised before Dental Procedures • Prosthetic heart valves • Prior endocarditis • Unrepaired cyanotic congenital heart disease, including palliative shunts • Completely repaired congenital heart defects during the 6 months after repair • Incompletely repaired congenital heart disease with residual defects adjacent to prosthetic material • Valvulopathy developing after cardiac transplantation

  36. Antibiotic Regimens for Prophylaxis of Endocarditis in Adults with High-Risk Cardiac Lesionsa,b A. Standard oral regimen • 1. Amoxicillin 2.0 g PO 1 h before procedure B. Inability to take oral medication • 1. Ampicillin 2.0 g IV or IM within 1 h before procedure

  37. C. Penicillin allergy • 1. Clarithromycin or azithromycin 500 mg PO 1 h before procedure • 2. Cephalexinc 2.0 g PO 1 h before procedure • 3. Clindamycin 600 mg PO 1 h before procedure D. Penicillin allergy, inability to take oral medication • 1. Cefazolinc or ceftriaxonec 1.0 g IV or IM 30 min before procedure • 2. Clindamycin 600 mg IV or IM 1 h before procedure

  38. THANK YOU

More Related